Navigation Links
Therapeutic AIDS vaccine designed by HIVACAT reduces the viral load in the majority of AIDS patients
Date:2/1/2011

The therapeutic vaccines are a priority research line of the HIVACAT, the catalan programme for the development of therapeutic vaccines and prevention against the Human Immunodeficiency Virus (HIV). This type of therapeutic vaccine helps the patients who are carriers of the virus, combat infection and control the appearance of AIDS in the same way as with the current antiretroviral treatments. The final aim of the therapeutic vaccines will be to avoid a life long treatment with antiretroviral drugs. The research team 'Infectious Diseases and AIDS' led by Dr. Josep Maria Gastell from IDIBAPS Hospital Clnic has developed using the brand HIVACAT, a model of the therapuetic vaccine based on the patient's own dendritic cells. This reduction in the viral load is still considered to be insuficient but it is the first therapeutic vaccine which has achieved a postive response in the majority of patients.

The Journal of Infectious Diseases has published the results of this study with Dr. Felipe Garca from the Infectious Diseases Unit of IDIBAPS Hospital Clinic, as first author and Dr. Teresa Gallart from the Immunology Laboratoy of the same centre as last author. The work counted on an international collaboration with teams from France, the Hpital Piti-Salptrire and the Universit Pierre et Marie Curie in Paris/INSERM, and the USA, the National Institute of Cancer in Maryland.

A total of 24 patients participated in this double blind clinical trial, half of whom formed the control Group and who did not receive the vaccine. None of these patients received antiretroviral treatment and to enter into the study had to maintain a good T lymphatic blood load (>450 per mm3). The vaccine was personalized and was made from the dendritic cells of each patient sensitized in the laboratory against an inactive form of their own virus. We are looking at a cell therapy that in the ambit of IDIBAPS received support from the Cell Therapy programme of the U
'/>"/>

Contact: Alex Argemi
aargemi@clinic.ub.es
34-932-275-700
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer
Source:Eurekalert

Page: 1 2

Related biology news :

1. Reportlinker Adds Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics
2. SAGE expands Therapeutic Advances series
3. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. FDA Clears Medivances Arctic Sun 5000 for Fastest, Easiest Therapeutic Temperature Management
5. Therapeutic Hypothermia journal launching in spring 2011
6. Discovery opens door to therapeutic development for FSH muscular dystrophy
7. Scripps Research scientists break barrier to creating potential therapeutic molecules
8. Biotherapeutic Innovations on Display at AAPS National Biotechnology Conference
9. Multistage nanovector system provides sustained delivery of siRNA cancer therapeutic in mice
10. AAPS presents therapeutic protein drug interactions workshop
11. Study shows potential for using algae to produce human therapeutic proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
(Date:11/18/2014)...   EyeLock Inc. , a market leader ... USA (Safran), a leading U.S. provider of ... partnership to offer comprehensive biometric identity solutions and ... screening and financial services markets. As ... through a nationwide network of 1,100 IdentoGO® Centers.  ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... and other senior female family members should play a key ... in non-Western societies. However, they are often overlooked by health ... see them as an obstacle to promoting good nutrition and ... extensive literature review published in the January issue of ...
... celebrates its 50,000th eBook, available on its online ... Springer,s position as the largest eBook publisher and ... comprehensive online collection of science, technology and medicine ... addition, as announced in October 2011, Springer will ...
... may soon benefit from an experimental drug being tested by ... Texas A&M College of Veterinary Medicine & Biomedical Sciences ... similar injuries. Funded through a three-year, $750,000 grant from ... has already proven effective in mice at UCSF. Now the ...
Cached Biology News:Research highlights key role grandmothers play in mother and child nutrition and health 2Research highlights key role grandmothers play in mother and child nutrition and health 3SpringerLink now offers more than 50,000 eBooks 2Saving dogs with spinal cord injuries 2
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Cytochroma today announced that it has appointed John Cunningham, ... Advisory Board. , Dr. Cunningham is Professor of Nephrology ... at the Royal Free Hospital, London. His early training ... in The University of London and Washington University ...
... , SLINGERLANDS, N.Y., Oct. 15 Sabre Technical Services ... to the problems experienced by U.S. homeowners and builders ... Sabre,s solution is an adaptation of its patented chlorine ... and smaller buildings. , Sabre has a long history ...
... ... Inc. announced that it completed its pre-IND meeting with the U.S. Food ... evaluate the safety and efficacy of Stemedica,s high potency proprietary allogeneic mesenchymal ... Based on a meeting October 13, 2009 with the FDA, Stemedica is ...
Cached Biology Technology:Cytochroma Appoints Dr. John Cunningham to its Scientific Advisory Board 2Cytochroma Appoints Dr. John Cunningham to its Scientific Advisory Board 3Sabre Announces Roll-Out of Permanent Solution to Chinese Drywall Problems 2Sabre Announces Roll-Out of Permanent Solution to Chinese Drywall Problems 3Stemedica Completes Meeting with the FDA 2Stemedica Completes Meeting with the FDA 3
BAI-1 (T-20)...
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
GOAT ANTI HUMAN PSA (ISOFORM 1)...
... peptide derived from the N-terminal region of ... Specificity: Specific for the N-terminus of the ... Dog Rat Mouse (positive controls: MDCK-II A431 ... heart blood vessel and brain mossy fiber ...
Biology Products: